Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.01, read 2026-10-27
Ethical passes the values gate
Price48.65 USD
Fair value44.38
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markup36.85+32.0% to today ✓Distribution gives way to Markup after a 9% rise in 4 weeks
2026-09-14Read Distribution33.66+44.5% to today Markup gives way to Distribution after a 26% rise in 11 weeks
2026-07-02Read Markup26.80+81.5% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Tenable Holdings, Inc. holds its Markup at $48.65. The statistical read favours the buyers, held for 29 days.
As held on the ledger · 2026-10-27
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 29 days
Price at the screen
$48.65
Valuation
677.83 trailing · 18.52 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.01
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.73%
Below 33%
Interest-bearing debt is just 23.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
12.27%
Below 33%
Cash held in interest-bearing accounts and securities is 12.3% of assets, under the one-third limit.
Pass
Receivables
26.72%
Below 49%
Money owed to the company is 26.7% of assets, under the 49% limit.
Pass
Revenue purity
1.60%
Below 5%
Only 1.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Tenable Holdings, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TENB's ethical verdict changes
Today TENB passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. A 9.1% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus Hold. The average target sits −27% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cybersecurity tool priced well beyond its worth
Picture a firm selling digital armour that promises to spot every crack in your defences. Tenable sells exactly that, yet the market values it as if profits were already flowing strongly and growth accelerating fast. We pass because the current price sits 22% above our fair value with revenue expanding just 10% and both profit margins and returns on equity still negative.
The forward multiple of 18.4 times earnings looks ordinary until you notice the business has yet to turn a profit. Analysts may cluster around a buy rating with a $30 median target, yet that sits below today's quote and leaves little margin for the execution risks that come with an unknown competitive moat. Ethical screens clear, but the numbers do not support ownership here.
High expectations baked into the share price leave little room for slower adoption or tougher competition in exposure management. A single quarter of missed growth could reset sentiment quickly. Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TENB trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup$40.67+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 59% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$40.67+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 59% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$40.67+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 59% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$40.67+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup$40.67+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$40.67+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markup$40.67+3.4%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markup$39.32+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$39.32+6.7%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29.
2026-10-11Markup · changed$36.85+1.8%Entry 7
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $29.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
